Endocannabinoid signaling is terminated by enzymatic hydrolysis; process that 2-Arachidonoylglycerol (2-AG) is mediated by monoacylglycerol lipase (MAGL). The MAGL inhibition increases 2-AG levels, an endocannabinoid that acts on CB1 and CB2 receptors. In inflammation, the neutrophils are the first leukocytes to migrate to the injury focus. The aim was to investigate the effects of MAGL inhibition (with JZL184) in the neutrophils recruitment and activity in a murine model of acute lung injury (ALI) induced by LPS. Fifty C57BL/ 6 male mice were used (5-10/group) and divided into vehicle + saline, vehicle + LPS, and JZL184 + LPS groups. Mice were treated with JZL184 (16 mg/kg) or vehicle and after 60 min they received a LPS intranasal instillation (100 lg/ mL; 1 lL/g) or saline.
Six, 24 and 48 h later mice were euthanized and bronchoalveolar lavage fluid and lungs were harvested to KC, MIP-2 and MPO analysis. The LPS was able to increase the KC, MIP-2 and MPO levels and the JZL184 treatment prevented all these parameters. The treatment with AM281 and AM230 (CB1 and CB2 antagonists, respectively), administered i.p. (2,5 and/or 5 mg/kg) 30 min before JZL184 treatment, showed that antagonists prevented the JZL184 anti-inflammatory effects. ALI establishment was evident 6, 24 and 48 h after LPS intranasal instillation and the MAGL inhibition has anti-inflammatory effects. CB1 and CB2 receptors were connected with JZL184 anti-inflammatory effects in ALI murine model. Cytomegalovirus (CMV) has been implicated as a factor in immunosenescence, including poor antibody response to influenza vaccination. The present investigation tested this implication in adults aged 60-91 (N = 98; 70% CMV seropositive) vaccinated for up to 5 years (n = 325 person-years). Interactions between CMV serostatus and chronological age, another cause of immunosenescence, and use of beta-blockers, a potential protection against latent virus reactivation, were tested. Peak antibody, corrected for baseline, and spring antibody persistence, corrected for peak, were assessed. In multilevel models with years at Level 1 and people at Level 2, there was no main effect of CMV serostatus on peak antibody, but there was a 3-way interaction between CMV serostatus, age, and beta-blockers (interaction: c = À.14, SE = .06, p < .03). In this interaction, age was negatively associated with peak antibody, but only among adults who were CMV + and taking beta-blockers (simple age slope: c = À .08, SE=.02, p <.0001). CMV + adults had less persistence (main effect: c = À.33, SE.14, p < .02). This effect was abrogated in CMV + adults taking beta-blockers (interaction: c = .56, SE = .29, p < .06).
CMV seropositivity therefore contributed to lower peak antibody and less persistence after influenza vaccination. The effects of beta blockade, however, differed. People taking beta-blockers were more vulnerable to negative effects of age and CMV on peak antibody response but less vulnerable to the negative effect of CMV on persistence. Inflammation can be a consequence of acute ischemic stroke (AIS), and a possible risk for neurobehavioral recovery. Moreover, a subset of AIS patients develop post-stroke depression (PSD), which can slow recovery and increase risk of recurrent stroke and mortality. Because proinflammatory cytokines can induce depression-like symptoms, AIS-related inflammation may influence the development of PSD. Therefore, we initiated recruitment of AIS patients to assess general and executive cognitive functioning, clinical depression, and proinflammatory cytokine levels. Assessments were conducted at three time points following hospital admission for AIS: (i) 1-2 days, (ii) 5-7 days, and (iii) 90 days. Depressive symptoms were measured using standard instruments (Hamilton Depression Scale, Beck Depression Inventory), with a structured diagnostic interview for clinical depression (SCID) given on Day 90. Cognitive function was measured using the RBANS. Additional measures of functional and neurological status were obtained using the modified Rankin Scale (mRS) and the NIH Stroke Scale. In this initial phase, only patients scoring mild-to-moderate on the NIHSS are included. To date, of patients completing all three assessments (N = 9), five showed elevated plasma IL-6 on admission, which receded on subsequent days. Further, PSD at Day 90 (N = 2 patients) was not associated with detectable IL-6 at any time point. Recruitment and assay for inflammatory indicators are ongoing to determine associations between proinflammatory cytokines, AIS and PSD.
